| Business Summary | | SafeScience
Inc.
is
a
biotechnology
company
developing
novel
pharmaceutical
products
based
on
carbohydrate
compounds.
The
Company's
lead
drug
candidate,
GBC-590,
a
potential
treatment
for
multiple
forms
of
cancer,
is
in
Phase
II
clinical
trials
for
pancreatic
and
colorectal
cancers.
The
Company
also
develops
agricultural
products.
The
Company's
near
term
objective
is
to
continue
to
proceed
through
the
various
phases
of
United
States
Food
and
Drug
Administration
(FDA)
clinical
trials
for
GBC-590
and
to
continue
to
pursue
federal
and
state
registration
of
its
agriculture
products
while
seeking
alternatives,
including
sale,
for
its
agricultural
products
business
area.
SafeScience
conducts
its
business
through
two
wholly
owned
subsidiaries:
International
Gene
Group,
Inc.
and
SafeScience
Products,
Inc. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | SafeScience,
Inc.
is
a
biotechnology
company
developing
novel
pharmaceutical
products
based
on
carbohydrate
compounds.
The
Company's
lead
drug
candidate,
GBC-590,
is
a
potential
treatment
for
multiple
forms
of
cancer.
For
the
six
months
ended
6/30/01,
the
Company
reported
no
revenue.
Net
loss
from
continuing
operations
decreased
26%
to
$4.9
million.
Lower
loss
reflects
$183
thousand
in
restructuring
credits
vs.
a
$1.7
million
charge
in
the
prior
year. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Brian Hughes, 46 Chairman | -- | Bradley Carver, 39 Pres,
CEO, Director | $180K | John Burns, Ph.D., 55 CFO | 155K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|